High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2

This publication has 18 references indexed in Scilit:

• High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2
  SLAS Discovery, 2020
• Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
  ACS Pharmacology & Translational Science, 2020
• Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
  Nature Communications, 2020
• Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
  Science, 2020
• Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  Nature, 2020
• The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
  Proceedings of the National Academy of Sciences, 2018
• CHO-S Antibody Titers >1 Gram/Liter Using Flow Electroporation-Mediated Transient Gene Expression followed by Rapid Migration to High-Yield Stable Cell Lines
  SLAS Discovery, 2015
• The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
  Antiviral Research, 2015
• X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases
  Journal of Medicinal Chemistry, 2014
• A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays
  SLAS Discovery, 1999